Ph Ib/II ACR-368 as Monother& Comb w/Gemcitabine in Plat-Res Ovarian Ca Endometrial Adenoca &Urothel

Cancer
Nataliya Mar
A Phase Ib/II Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
Corpus Uteri
Kidney
Other Urinary
Ovary
Urinary Bladder

Study Description

This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status.

Eligibility

  • Participant must have histologically confirmed, locally advanced (i.e., not amenable to curative surgery and/or radiation therapy) or metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen.
  • Participant must be willing to provide tissue from a newly obtained tumor biopsy from an accessible tumor lesion not previously irradiated after signed informed consent.
  • Participant must have an estimated life expectancy of longer than 3 months.
  • Participant with known symptomatic brain metastases requiring > 10 mg/day of prednisolone (or its equivalent).
  • Participants has known human immunodeficiency virus, hepatitis B, or hepatitis C infection that is considered uncontrolled
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.